OA11749A - Tricyclic inhibitors of poly(adp-ribose)polymerases. - Google Patents

Tricyclic inhibitors of poly(adp-ribose)polymerases. Download PDF

Info

Publication number
OA11749A
OA11749A OA1200100183A OA1200100183A OA11749A OA 11749 A OA11749 A OA 11749A OA 1200100183 A OA1200100183 A OA 1200100183A OA 1200100183 A OA1200100183 A OA 1200100183A OA 11749 A OA11749 A OA 11749A
Authority
OA
OAPI
Prior art keywords
mmol
compound
tetrahydro
alkyl
azepino
Prior art date
Application number
OA1200100183A
Other languages
English (en)
Inventor
Stacie S Canan-Koch
Lars Henrik Thoresen
Jayashree Girish Tikhe
Stephen Evan Webber
Original Assignee
Agouron Pharma
Cancer Res Campaign Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma, Cancer Res Campaign Tech filed Critical Agouron Pharma
Publication of OA11749A publication Critical patent/OA11749A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
OA1200100183A 1999-01-11 2000-01-10 Tricyclic inhibitors of poly(adp-ribose)polymerases. OA11749A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11543199P 1999-01-11 1999-01-11

Publications (1)

Publication Number Publication Date
OA11749A true OA11749A (en) 2005-07-19

Family

ID=22361361

Family Applications (2)

Application Number Title Priority Date Filing Date
OA1200100183A OA11749A (en) 1999-01-11 2000-01-10 Tricyclic inhibitors of poly(adp-ribose)polymerases.
OA1200200262A OA12185A (en) 1999-01-11 2002-08-28 Tricyclic inhibitors of poly(adp-ribose)polymerases.

Family Applications After (1)

Application Number Title Priority Date Filing Date
OA1200200262A OA12185A (en) 1999-01-11 2002-08-28 Tricyclic inhibitors of poly(adp-ribose)polymerases.

Country Status (40)

Country Link
US (4) US6495541B1 (fr)
EP (1) EP1140936B1 (fr)
JP (1) JP4093448B2 (fr)
KR (1) KR100632079B1 (fr)
CN (1) CN100418967C (fr)
AP (1) AP1538A (fr)
AT (1) ATE261963T1 (fr)
AU (1) AU781711B2 (fr)
BG (1) BG65210B1 (fr)
BR (1) BRPI0008614B8 (fr)
CA (1) CA2360003C (fr)
CZ (1) CZ302941B6 (fr)
DE (1) DE60009033T2 (fr)
DK (1) DK1140936T3 (fr)
EA (1) EA004989B1 (fr)
EE (1) EE05006B1 (fr)
ES (1) ES2218110T3 (fr)
GE (1) GEP20033055B (fr)
HK (1) HK1040992A1 (fr)
HR (1) HRP20010573B1 (fr)
HU (1) HU229875B1 (fr)
ID (1) ID30138A (fr)
IL (2) IL144112A0 (fr)
IS (1) IS5995A (fr)
LT (1) LT4936B (fr)
LV (1) LV12770B (fr)
MX (1) MXPA01007001A (fr)
NO (1) NO320343B1 (fr)
NZ (1) NZ512731A (fr)
OA (2) OA11749A (fr)
PL (1) PL210415B1 (fr)
PT (1) PT1140936E (fr)
RO (1) RO121778B1 (fr)
RS (1) RS50031B (fr)
SI (1) SI20691B (fr)
SK (1) SK287338B6 (fr)
TR (1) TR200102005T2 (fr)
UA (1) UA75034C2 (fr)
WO (1) WO2000042040A1 (fr)
ZA (1) ZA200105399B (fr)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143349A0 (en) * 1999-09-28 2002-04-21 Basf Ag Azepinoindole derivatives, the production and use thereof
US6589725B1 (en) 1999-10-25 2003-07-08 Rigel Pharmaceuticals, Inc. Tankyrase H, compositions involved in the cell cycle and methods of use
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
WO2001070674A1 (fr) * 2000-03-20 2001-09-27 N-Gene Research Laboratories Inc. Derives amidoxime d'acide propenecarboxylique, leur procede de preparation, et compositions pharmaceutiques renfermant ces derives
US6534651B2 (en) 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
CA2430363C (fr) 2000-12-01 2010-04-13 Guilford Pharmaceuticals Inc. Composes et leurs utilisations
JP2004528376A (ja) 2001-05-08 2004-09-16 クドス ファーマシューティカルズ リミテッド Ｐａｒｐ阻害薬としてのイソキノリノン誘導体
JP2005501848A (ja) 2001-08-15 2005-01-20 アイコス コーポレイション ２ｈ−フタラジン−１−オンおよびその使用方法
US20030096833A1 (en) 2001-08-31 2003-05-22 Jagtap Prakash G. Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
AU2002358650A1 (en) * 2001-12-14 2003-06-30 Altana Pharma Ag Known and novel 4,5-dihydro-imidazo(4,5,1-ij)quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
AU2004203977B2 (en) * 2003-01-09 2010-06-17 Pfizer Inc. Diazepinoindole derivatives as kinase inhibitors
AU2004258801A1 (en) 2003-02-28 2005-02-03 Inotek Pharmaceuticals Corporation Tetracyclic Benzamide Derivatives and methods of use thereof
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
BRPI0408996A (pt) * 2003-03-31 2006-03-28 Pfizer saia de inibidores tricìclicos de poli(adpp-ribose) polimerases
WO2004105700A2 (fr) * 2003-05-28 2004-12-09 Guildford Pharmaceuticals, Inc. Composes, procedes et compositions pharmaceutiques destines a l'inhibition de la parp
WO2005012305A2 (fr) * 2003-07-25 2005-02-10 Cancer Research Technology Limited Composes therapeutiques
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
DK2305221T3 (en) 2003-12-01 2015-08-24 Kudos Pharm Ltd DNA damage repair inhibitors for the treatment of cancer
EP1722797A4 (fr) 2004-02-26 2008-03-19 Inotek Pharmaceuticals Corp Derives d'isoquinoline et methodes d'utilisation
BRPI0515567A (pt) * 2004-09-22 2008-07-29 Pfizer combinações terapêuticas compreendendo inibidor de poli (adp-ribose) polimerase
CN101133061B (zh) * 2004-09-22 2011-09-07 辉瑞有限公司 8-氟-2-{4-[（甲基氨基）甲基]苯基}-1,3,4,5-四氢-6H-氮杂卓并[5,4,3-cd]吲哚-6-酮的磷酸盐的多晶型物和非晶物
BRPI0516766A (pt) * 2004-09-22 2008-09-16 Pfizer formas polimórficas e amorfas do sal de fosfato de 8-flúor-2{4-[(metilamino)metil]fenil}-1,3,4,5-tetraidro- 6h-azepino[5,4,3-cd]indol-6-ona, composição farmacêutica, formas de dosagens e respectivo uso
KR100876520B1 (ko) * 2004-09-22 2008-12-31 화이자 인코포레이티드 폴리(ａｄｐ-리보오스) 폴리머라제 억제제의 제조 방법
CN101223175B (zh) 2005-01-19 2013-03-27 卫材有限公司 二氮杂苯并[de]蒽-3-酮化合物及抑制PARP的方法
KR20070116011A (ko) 2005-02-25 2007-12-06 이노텍 파마슈티컬스 코포레이션 테트라사이클릭 아미노 및 카복사미도 화합물 및 이의 이용방법
US7297700B2 (en) 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
DE102005022111A1 (de) * 2005-05-12 2006-11-16 Siemens Ag Verfahren zum Datenaustausch
EP1908481A1 (fr) * 2005-06-24 2008-04-09 Ono Pharmaceutical Co., Ltd. Agent pour réduire le saignement lors de troubles cérébrovasculaires
CN101213190A (zh) 2005-07-14 2008-07-02 Irm责任有限公司 用作tpo模拟物的化合物和组合物
ZA200800907B (en) 2005-07-18 2010-04-28 Bipar Sciences Inc Treatment of cancer
JP2009506060A (ja) 2005-08-24 2009-02-12 イノテック ファーマシューティカルズ コーポレイション インデノイソキノリノン類縁体及びそれらの使用方法
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
SI2338487T1 (sl) * 2006-01-17 2014-01-31 Abbott Laboratories Kombinacijska terapija z inhibitorji PARP
TWI464148B (zh) 2006-03-16 2014-12-11 Evotec Us Inc 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US7994222B2 (en) 2006-09-05 2011-08-09 Bipar Sciences, Inc. Monitoring of the inhibition of fatty acid synthesis by iodo-nitrobenzamide compounds
JP2010502730A (ja) 2006-09-05 2010-01-28 バイパー サイエンシズ，インコーポレイティド 癌の治療法
CA2677046A1 (fr) 2007-02-28 2008-09-04 Inotek Pharmaceuticals Corporation Analogues d'indenoisoquinoleinone et procedes d'utilisation de ceux-ci
WO2008154129A1 (fr) * 2007-06-08 2008-12-18 Bausch & Lomb Incorporated Compositions pharmaceutiques et procédé permettant de traiter, réduire, améliorer, atténuer, ou prévenir la sécheresse oculaire
CN101809017A (zh) 2007-09-14 2010-08-18 阿斯利康(瑞典)有限公司 酞嗪酮衍生物
DK2209375T3 (da) 2007-10-03 2014-10-06 Eisai Inc Parp-inhibitorforbindelser, præparater og fremgangsmåder til anvendelse deraf
JP2011503111A (ja) 2007-11-12 2011-01-27 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
GB0804755D0 (en) 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2346495B2 (fr) 2008-10-07 2023-05-24 Kudos Pharmaceuticals Limited Formulation pharmaceutique 514
WO2011058367A2 (fr) 2009-11-13 2011-05-19 Astrazeneca Ab Test de diagnostic pour prédire la sensibilité à un traitement par un inhibiteur de poly(adp-ribose) polymérase
KR100986820B1 (ko) * 2010-01-27 2010-10-12 (주)에코베이스 막힘방지형 고효율 산기장치 및 이를 이용한 수질정화장치
RS59494B1 (sr) 2010-02-12 2019-12-31 Pfizer Soli i polimorfi 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4, 3-cd]indol-6-ona
ES2590682T3 (es) 2010-12-02 2016-11-23 Shanghai De Novo Pharmatech Co Ltd. Derivados heterocíclicos, procesos de preparación y usos médicos de los mismos
EA027533B1 (ru) 2011-12-31 2017-08-31 Бейджен, Лтд. Конденсированные тетра- или пентациклические дигидродиазепинокарбазолоны в качестве ингибиторов parps
EP2797919B1 (fr) 2011-12-31 2017-03-29 BeiGene, Ltd. Pyridophthalazinones tétra ou pentacycliques fusionnés à utiliser en tant qu'inhibiteurs de parp
EP2918292B1 (fr) 2012-11-08 2019-12-11 Nippon Kayaku Kabushiki Kaisha Composé polymère comprenant un composé camptothécine et un amplificateur de l'effet anti-cancéreux associé à celui-ci, et son utilisation
ES2700348T3 (es) 2014-01-05 2019-02-15 Univ Washington Trazadores radioetiquetados para poli (ADP-ribosa) polimerasa-1 (PARP-1), métodos y usos para estos
CN103772395B (zh) * 2014-01-23 2016-05-11 中国药科大学 一类具有parp抑制活性的化合物、其制备方法及用途
DK3157566T3 (da) 2014-06-17 2019-07-22 Vertex Pharma Fremgangsmåde til behandling af cancer under anvendelse af en kombination chk1- og atr-inhibitorer
EP3182975A4 (fr) 2014-08-22 2018-04-18 Clovis Oncology, Inc. Comprimés de rucaparib à dosage élevé
CN105607772B (zh) * 2014-11-13 2020-11-03 现代自动车株式会社 触摸输入装置以及包括该装置的车辆
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
WO2016138574A1 (fr) 2015-03-02 2016-09-09 Sinai Health System Facteurs de recombinaison homologue
KR101896567B1 (ko) 2015-07-23 2018-09-07 인스티튜트 큐리 암 치료를 위한 디베이트 분자와 parp 억제제의 병용 용도
IL257442B2 (en) 2015-08-25 2023-03-01 Beigene Ltd Process for preparing parp inhibitor, crystalline forms and their uses
RU2768621C1 (ru) 2015-09-30 2022-03-24 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с использованием комбинации повреждающих днк средств и ингибиторов atr
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
CN107286166B (zh) * 2016-04-11 2020-03-31 上海勋和医药科技有限公司 取代1，3，4，5-四氢-6h-吡咯并[4，3，2-ef][2]苯并氮杂-6-酮衍生物
WO2018022851A1 (fr) 2016-07-28 2018-02-01 Mitobridge, Inc. Méthode de traitement de lésions rénales aiguës.
WO2018059437A1 (fr) 2016-09-27 2018-04-05 Beigene, Ltd. Traitement de cancers à l'aide d'une combinaison comprenant des inhibiteurs de parp
JP6541635B2 (ja) * 2016-10-28 2019-07-10 ベイジーン リミテッド Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
KR20190107656A (ko) 2016-11-02 2019-09-20 이뮤노젠 아이엔씨 항체-약물 콘주게이트 및 parp 억제제로 병용 치료
CN106854172B (zh) * 2016-12-11 2019-04-19 山东轩德医药科技有限公司 一种6-氟-1h-吲哚-4-甲酸甲酯的制备方法
WO2018122168A1 (fr) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinaisons d'inhibiteurs de kinase bub1 et d'inhibiteurs de parp
EP3573990A1 (fr) * 2017-01-24 2019-12-04 Assia Chemical Industries Ltd. Formes à l'état solide de rucaparib et de sels de rucaparib
CN106748958B (zh) * 2017-01-25 2018-12-18 伦俊杰 一种Rucaparib中间体的制备方法
CN110392687B (zh) 2017-02-28 2022-08-02 百济神州(苏州)生物科技有限公司 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式及其用途
WO2018162439A1 (fr) 2017-03-08 2018-09-13 Onxeo Nouveau biomarqueur prédictif de la sensibilité à un traitement du cancer avec une molécule dbait
US11161865B2 (en) 2017-05-24 2021-11-02 The Trustees Of The University Of Pennsylvania Radiolabeled and fluorescent PARP inhibitors for imaging and radiotherapy
IT201700085789A1 (it) 2017-07-26 2019-01-26 Olon Spa Metodo per la preparazione di rucaparib ad elevata purezza
CA3071345A1 (fr) * 2017-07-28 2019-01-31 Yale University Medicaments anticancereux et leurs procedes de fabrication et d'utilisation
CN109651377B (zh) * 2017-10-12 2020-10-20 成都海创药业有限公司 一种治疗癌症的化合物及其用途
CN109651376B (zh) * 2017-10-12 2022-06-03 江苏创诺制药有限公司 一种氮杂卓并[5,4,3-cd]吲哚-6-酮化合物的合成方法
CA3080657A1 (fr) * 2017-11-03 2019-05-09 Sandoz Ag Sel cristallin d'un inhibiteur de poly(adp-ribose) polymerase tricyclique
US11220507B2 (en) 2017-12-15 2022-01-11 Advitech Advisory And Technologies Sa Process for the preparation of rucaparib and novel synthesis intermediates
WO2019130229A1 (fr) 2017-12-28 2019-07-04 Mylan Laboratories Ltd Procédés et intermédiaires pouvant être utilisés pour la préparation de rucaparib
JP7356450B2 (ja) * 2018-01-05 2023-10-04 サイブレクサ １・インコーポレイテッド 酸性または低酸素の疾患組織を含む疾患の治療のための化合物、組成物、及び方法
US10442813B2 (en) 2018-01-30 2019-10-15 RK Pharma Solutions LLC Polymorphs of rucaparib camsylate and methods of making same
CN110229162B (zh) * 2018-03-05 2020-08-11 新发药业有限公司 一种瑞卡帕布的简便制备方法
CA3092779A1 (fr) 2018-03-13 2019-09-19 Onxeo Molecule dbait contre la resistance acquise dans le traitement du cancer
CN110272419A (zh) * 2018-03-14 2019-09-24 上海艾力斯医药科技有限公司 二氢吡啶并酞嗪酮衍生物、其制备方法及应用
WO2019207596A1 (fr) 2018-04-25 2019-10-31 Mylan Laboratories Limited Nouvelles formes cristallines du sel de rucaparib (s)-camsylate et base exempte de rucaparib
CN108743557A (zh) * 2018-06-27 2018-11-06 李莉 一种磷酸瑞卡帕布软胶囊及其制备方法
CN108976236B (zh) * 2018-08-16 2020-11-10 湖南华腾制药有限公司 一种氘代parp抑制剂、其盐、其制备方法及用途
CN111217818A (zh) 2018-11-27 2020-06-02 台耀化学股份有限公司 芦卡帕尼樟脑磺酸盐的结晶、及制备三环化合物、芦卡帕尼及其樟脑磺酸盐结晶的方法
EP3919495A4 (fr) * 2019-02-02 2022-10-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Analogue d'indolo-heptamyl-oxime en tant qu'inhibiteur de parp
CN110256468B (zh) * 2019-05-14 2020-09-01 山东省分析测试中心 双吲哚生物碱化合物或其药学上可接受的盐及其制备方法和应用
CN114206864B (zh) 2019-05-14 2024-05-24 苏州四体康宸医药科技有限公司 喹唑啉-2.4-二酮衍生物作为parp抑制剂
JP2022541747A (ja) 2019-07-10 2022-09-27 サイブレクサ ３，インコーポレイテッド 治療薬としての微小管標的化剤のペプチドコンジュゲート
AU2020309570A1 (en) 2019-07-10 2022-02-03 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
CN114072410B (zh) * 2019-08-01 2023-08-01 正大天晴药业集团股份有限公司 作为parp抑制剂吲哚并七元酰肟化合物
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
WO2021156140A1 (fr) 2020-02-03 2021-08-12 Sandoz Ag Polymorphe de mésylate de rucaparib
WO2021169984A1 (fr) 2020-02-24 2021-09-02 甫康（上海）健康科技有限责任公司 Application anti-coronavirus de l'inhibiteur de la poly adp-ribose polymérase
AU2021262569A1 (en) 2020-04-28 2022-11-24 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(ADP-ribose) polymerase (PARP) inhibitors
CN111646990B (zh) * 2020-05-22 2023-01-10 同济大学 一种3,4-桥环吲哚类化合物的制备方法及Rucaparib的合成方法
CN111662299B (zh) * 2020-07-10 2022-07-26 中山大学 一种取代吲哚并氮杂酮类化合物及其制备方法和应用
EP4182318A1 (fr) 2020-07-14 2023-05-24 Assia Chemical Industries Ltd Formes à l'état solide de sels de rucaparib
CN115698019A (zh) * 2020-07-31 2023-02-03 正大天晴药业集团股份有限公司 用作parp抑制剂的吲哚并七元酰肟类似物的结晶及其制备方法
CN111961047A (zh) * 2020-08-19 2020-11-20 南通大学 一种6-乙氧基-3,4-二氢-2,7-萘啶-1（2h）-酮及其合成方法
WO2022090938A1 (fr) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Dérivés de phtalazinone utiles en tant qu'inhibiteurs de parp
AU2022206297A1 (en) 2021-01-08 2023-08-03 Cybrexa 2, Inc. Process for preparing a conjugate linking moiety
WO2022155172A1 (fr) 2021-01-13 2022-07-21 Cybrexa 3, Inc. Conjugués peptidiques d'agents thérapeutiques
JP2024515338A (ja) 2021-04-08 2024-04-09 ライゼン ファーマシューティカルズ アーゲー ポリ（ａｄｐ－リボース）ポリメラーゼの阻害剤
IL308326A (en) * 2021-05-18 2024-01-01 Onconic Therapeutics Inc A crystalline form of a tricyclic derivative compound, a method for its preparation and a pharmaceutical composition comprising the same
WO2023137060A1 (fr) 2022-01-11 2023-07-20 Assia Chemical Industries Ltd. Formes à l'état solide de tosylate de rucaparib
WO2023201338A1 (fr) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Polythérapie comprenant un inhibiteur de mat2a et un inhibiteur de parp
WO2023233295A1 (fr) 2022-06-01 2023-12-07 Ideaya Biosciences, Inc. Dérivés de thiadiazolyle utilisés en tant qu'inhibiteurs d'adn polymérase thêta et leurs utilisations

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642820A (en) 1969-11-03 1972-02-15 Upjohn Co 4 5-dihydropyrrolo(3 2 1-jk)(1 4)bezodiazepines
US3883590A (en) 1971-06-01 1975-05-13 Universal Oil Prod Co Preparation of n-alkylarylcarboxamides
DE2322434A1 (de) 1973-05-04 1974-11-21 Bayer Ag 2-trifluormethylimino-1,3-dithioloeckige klammer auf 4,5-b eckige klammer zu -chinoxaline, verfahren zu ihrer herstellung, sowie ihre verwendung als insektizide, akarizide und fungizide
US4033960A (en) 1973-07-31 1977-07-05 Bayer Aktiengesellschaft 2-Mercaptoquinoxaline-di-N-oxide products and a method for their preparation
US3950343A (en) 1973-11-06 1976-04-13 Ayerst, Mckenna And Harrison Ltd. Pyrroloisoquinoline derivatives
US3900477A (en) * 1973-11-06 1975-08-19 Ayerst Mckenna & Harrison 5-amino-and 5-hydrazinodihydropyrroloisoquinoline derivatives
US3978066A (en) 1973-11-06 1976-08-31 Ayerst, Mckenna And Harrison Ltd. Certain 4,6-dihydropyrrolotriazoline-quinoline derivatives
US3959343A (en) * 1974-10-25 1976-05-25 Wako Pure Chemical Industries, Ltd. Process for producing hydrazonitriles
DE2913728A1 (de) 1979-04-05 1980-10-16 Bayer Ag 2-sulfonyl-chinoxaline, verfahren zu ihrer herstellung sowie ihre verwendung als mikrobizide
DE3103137A1 (de) 1981-01-30 1982-08-26 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung aliphatischer cyclischer kohlensaeureester
JPS57144286A (en) 1981-03-02 1982-09-06 Takeda Chem Ind Ltd Azepinoindole derivative and its preparation
US5215738A (en) 1985-05-03 1993-06-01 Sri International Benzamide and nicotinamide radiosensitizers
US4910193A (en) 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
JPS6434988A (en) * 1987-07-30 1989-02-06 Kissei Pharmaceutical Azepinoindole derivative
DE4125292A1 (de) * 1991-07-31 1993-02-04 Kali Chemie Pharma Gmbh 6-oxo-azepinoindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB9117987D0 (en) 1991-08-20 1991-10-09 Ici Plc Heterocyclic compounds
US5342946A (en) 1992-12-02 1994-08-30 Guilford Pharmaceuticals Inc. Phosphonoalkylquinolin-2-ones as novel antagonists of non-NMDA ionotropic excitatory amino acid receptors
WO1995009159A1 (fr) 1993-09-28 1995-04-06 Otsuka Pharmaceutical Company, Limited Derives de quinoxaline utilises comme agents antidiabetiques
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US5561161A (en) 1994-03-25 1996-10-01 Oxigene, Inc. Methods of administering and pharmaceutical formulations containing n-substituted benzamides and/or acid addition salts thereof
US5589483A (en) 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
ES2105959B1 (es) 1995-01-17 1998-07-01 Zeneca Pharma Sa Derivados de 1,4-dioxido de quinoxalina, procedimiento de preparacion y de utilizacion.
US5756548A (en) 1995-04-03 1998-05-26 Centaur Pharmaceuticals, Inc. Acetamidobenzamide compounds for neurodegenerative disorders
US5659082A (en) 1995-04-03 1997-08-19 Centaur Pharmaceuticals, Inc. Nitro- and aminobenzamide compounds for neurodegenerative disorders
HUP9901092A3 (en) * 1995-08-02 2001-11-28 Univ Newcastle Ventures Ltd Benzimidazole compounds and their pharmaceutical use
HUT76302A (en) 1995-11-30 1997-07-28 Chinoin Gyogyszer Es Vegyeszet Quinoxaline derivatives, pharmaceutical compositions containing them and process for producing them
US6028111A (en) 1996-03-08 2000-02-22 Oxigene, Inc. Compositions and use of benzamides and nicotinamides as anti-inflammatory agents
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
BR9809115A (pt) 1997-05-13 2002-01-02 Octamer Inc Métodos para tratar inflamação e doenças inflamatórias usando inibidores de padprt
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US20020028813A1 (en) 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
WO1999011622A1 (fr) 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Composes aminosubstitues, et procedes et compositions permettant d'inhiber l'activite de la parp
WO1999011644A1 (fr) 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Composes di-n-heterocycliques, et procedes et compositions permettant d'inhiber l'activite de la parp
CA2332239A1 (fr) * 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Composes condenses tricycliques inhibant l'activite de type poly(adp-ribose) polymerase (parp)
EP1077944A1 (fr) 1998-05-15 2001-02-28 Guilford Pharmaceuticals Inc. Composes de carboxamide, compositions et methodes d'inhibition de l'activite de type poly(adp-ribose) polymerase (parp)
DE19946289A1 (de) 1999-09-28 2001-03-29 Basf Ag Benzodiazepin-Derivate, deren Herstellung und Anwendung
IL143349A0 (en) 1999-09-28 2002-04-21 Basf Ag Azepinoindole derivatives, the production and use thereof

Also Published As

Publication number Publication date
AP1538A (en) 2006-01-10
EE200100364A (et) 2002-10-15
MXPA01007001A (es) 2002-07-30
DE60009033T2 (de) 2004-08-05
PL357049A1 (en) 2004-07-12
US7429578B2 (en) 2008-09-30
BG105811A (en) 2002-05-31
AP2001002211A0 (en) 2001-09-30
PT1140936E (pt) 2004-06-30
AU781711B2 (en) 2005-06-09
EP1140936B1 (fr) 2004-03-17
US6495541B1 (en) 2002-12-17
EA004989B1 (ru) 2004-10-28
US20060009517A1 (en) 2006-01-12
SI20691B (sl) 2008-10-31
HRP20010573B1 (en) 2006-04-30
SK287338B6 (sk) 2010-07-07
HUP0105414A3 (en) 2003-04-28
HK1040992A1 (en) 2002-06-28
EE05006B1 (et) 2008-04-15
CZ20012443A3 (cs) 2002-02-13
CN1342161A (zh) 2002-03-27
SK9662001A3 (en) 2002-04-04
ATE261963T1 (de) 2004-04-15
BR0008614A (pt) 2001-10-16
RO121778B1 (ro) 2008-04-30
BRPI0008614B8 (pt) 2021-05-25
PL210415B1 (pl) 2012-01-31
NO320343B1 (no) 2005-11-28
HU229875B1 (en) 2014-11-28
KR100632079B1 (ko) 2006-10-04
BG65210B1 (bg) 2007-07-31
DE60009033D1 (de) 2004-04-22
SI20691A (sl) 2002-04-30
HUP0105414A2 (hu) 2002-05-29
US6977298B2 (en) 2005-12-20
LT4936B (lt) 2002-07-25
NO20013313D0 (no) 2001-07-04
US20050085460A1 (en) 2005-04-21
EP1140936A1 (fr) 2001-10-10
ES2218110T3 (es) 2004-11-16
LV12770B (lv) 2002-05-20
IS5995A (is) 2001-07-10
CZ302941B6 (cs) 2012-01-25
HRP20010573A2 (en) 2005-02-28
CN100418967C (zh) 2008-09-17
IL144112A (en) 2006-07-05
WO2000042040A1 (fr) 2000-07-20
CA2360003C (fr) 2012-07-10
JP4093448B2 (ja) 2008-06-04
US20030078254A1 (en) 2003-04-24
NZ512731A (en) 2004-01-30
YU49001A (sh) 2005-11-28
OA12185A (en) 2006-05-09
ZA200105399B (en) 2002-07-01
RS50031B (sr) 2008-11-28
EA200100764A1 (ru) 2002-06-27
DK1140936T3 (da) 2004-06-21
CA2360003A1 (fr) 2000-07-20
IL144112A0 (en) 2002-05-23
ID30138A (id) 2001-11-08
BR0008614B1 (pt) 2014-11-25
KR20020008112A (ko) 2002-01-29
LT2001083A (en) 2002-03-25
NO20013313L (no) 2001-09-10
GEP20033055B (en) 2003-08-25
UA75034C2 (en) 2006-03-15
TR200102005T2 (tr) 2001-12-21
LV12770A (en) 2001-12-20
JP2002534523A (ja) 2002-10-15
AU2408800A (en) 2000-08-01

Similar Documents

Publication Publication Date Title
OA11749A (en) Tricyclic inhibitors of poly(adp-ribose)polymerases.
EP1208104B1 (fr) Inhibiteurs tricycliques de poly(adp-ribose) polymerases
CA2762226C (fr) Derives isoquinolein-1(2h)-one en tant qu'inhibiteurs de parp-1
WO2003106430A1 (fr) Inhibiteurs benzimidazole de la poly(adp-ribosyl) polymerase
IL181322A (en) Method of preparing poly(adp-ribose) polymerase inhibitors
EP1899334A2 (fr) Composes de naphthyridine
JP2019536759A (ja) 置換された二環式ヘテロアリール系ニコチン性アセチルコリン受容体アロステリック調節剤
JP2015523352A (ja) Ｋａｔｉｉ阻害剤としての三環式化合物